PubMed:16867021 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCoin-entities

LitCoin-sentences

{"project":"LitCoin-sentences","denotations":[{"id":"T1","span":{"begin":0,"end":87},"obj":"Sentence"},{"id":"T2","span":{"begin":88,"end":209},"obj":"Sentence"},{"id":"T3","span":{"begin":210,"end":421},"obj":"Sentence"},{"id":"T4","span":{"begin":422,"end":744},"obj":"Sentence"},{"id":"T5","span":{"begin":745,"end":894},"obj":"Sentence"},{"id":"T6","span":{"begin":895,"end":988},"obj":"Sentence"},{"id":"T7","span":{"begin":989,"end":1150},"obj":"Sentence"},{"id":"T8","span":{"begin":1151,"end":1290},"obj":"Sentence"},{"id":"T9","span":{"begin":1291,"end":1394},"obj":"Sentence"},{"id":"T10","span":{"begin":1395,"end":1476},"obj":"Sentence"},{"id":"T11","span":{"begin":1477,"end":1535},"obj":"Sentence"},{"id":"T12","span":{"begin":1536,"end":1720},"obj":"Sentence"},{"id":"T13","span":{"begin":1721,"end":1818},"obj":"Sentence"},{"id":"T14","span":{"begin":1819,"end":1929},"obj":"Sentence"}],"text":"Antipsychotic-like profile of thioperamide, a selective H3-receptor antagonist in mice.\nExperimental and clinical evidence points to a role of central histaminergic system in the pathogenesis of schizophrenia. The present study was designed to study the effect of histamine H(3)-receptor ligands on neuroleptic-induced catalepsy, apomorphine-induced climbing behavior and amphetamine-induced locomotor activities in mice. Catalepsy was induced by haloperidol (2 mg/kg p.o.), while apomorphine (1.5 mg/kg s.c.) and amphetamine (2 mg/kg s.c.) were used for studying climbing behavior and locomotor activities, respectively. (R)-alpha-methylhistamine (RAMH) (5 microg i.c.v.) and thioperamide (THP) (15 mg/kg i.p.), per se did not cause catalepsy. Administration of THP (3.75, 7.5 and 15 mg/kg i.p.) 1 h prior to haloperidol resulted in a dose-dependent increase in the catalepsy times (P \u003c 0.05). However, pretreatment with RAMH significantly reversed such an effect of THP (15 mg/kg i.p.). RAMH per se showed significant reduction in locomotor time, distance traveled and average speed but THP (15 mg/kg i.p.) per se had no effect on these parameters. On amphetamine-induced hyperactivity, THP (3.75 and 7.5 mg/kg i.p.) reduced locomotor time, distance traveled and average speed (P \u003c 0.05). Pretreatment with RAMH (5 microg i.c.v.) could partially reverse such effects of THP (3.75 mg/kg i.p.). Climbing behavior induced by apomorphine was reduced in animals treated with THP. Such an effect was, however, reversed in presence of RAMH. THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice. Such effects of THP were reversed by RAMH indicating the involvement of histamine H(3)-receptors. Findings suggest a potential for H(3)-receptor antagonists in improving the refractory cases of schizophrenia."}

LitCoin-entities-OrganismTaxon-PD

{"project":"LitCoin-entities-OrganismTaxon-PD","denotations":[{"id":"T1","span":{"begin":82,"end":86},"obj":"OrganismTaxon"},{"id":"T3","span":{"begin":416,"end":420},"obj":"OrganismTaxon"},{"id":"T5","span":{"begin":1715,"end":1719},"obj":"OrganismTaxon"}],"attributes":[{"id":"A1","pred":"db_id","subj":"T1","obj":"NCBItxid:10095"},{"id":"A2","pred":"db_id","subj":"T1","obj":"NCBItxid:10088"},{"id":"A3","pred":"db_id","subj":"T3","obj":"NCBItxid:10095"},{"id":"A4","pred":"db_id","subj":"T3","obj":"NCBItxid:10088"},{"id":"A5","pred":"db_id","subj":"T5","obj":"NCBItxid:10095"},{"id":"A6","pred":"db_id","subj":"T5","obj":"NCBItxid:10088"}],"text":"Antipsychotic-like profile of thioperamide, a selective H3-receptor antagonist in mice.\nExperimental and clinical evidence points to a role of central histaminergic system in the pathogenesis of schizophrenia. The present study was designed to study the effect of histamine H(3)-receptor ligands on neuroleptic-induced catalepsy, apomorphine-induced climbing behavior and amphetamine-induced locomotor activities in mice. Catalepsy was induced by haloperidol (2 mg/kg p.o.), while apomorphine (1.5 mg/kg s.c.) and amphetamine (2 mg/kg s.c.) were used for studying climbing behavior and locomotor activities, respectively. (R)-alpha-methylhistamine (RAMH) (5 microg i.c.v.) and thioperamide (THP) (15 mg/kg i.p.), per se did not cause catalepsy. Administration of THP (3.75, 7.5 and 15 mg/kg i.p.) 1 h prior to haloperidol resulted in a dose-dependent increase in the catalepsy times (P \u003c 0.05). However, pretreatment with RAMH significantly reversed such an effect of THP (15 mg/kg i.p.). RAMH per se showed significant reduction in locomotor time, distance traveled and average speed but THP (15 mg/kg i.p.) per se had no effect on these parameters. On amphetamine-induced hyperactivity, THP (3.75 and 7.5 mg/kg i.p.) reduced locomotor time, distance traveled and average speed (P \u003c 0.05). Pretreatment with RAMH (5 microg i.c.v.) could partially reverse such effects of THP (3.75 mg/kg i.p.). Climbing behavior induced by apomorphine was reduced in animals treated with THP. Such an effect was, however, reversed in presence of RAMH. THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice. Such effects of THP were reversed by RAMH indicating the involvement of histamine H(3)-receptors. Findings suggest a potential for H(3)-receptor antagonists in improving the refractory cases of schizophrenia."}

LitCoin_Mondo

{"project":"LitCoin_Mondo","denotations":[{"id":"T1","span":{"begin":195,"end":208},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":1915,"end":1928},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"0005090"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"0005090"}],"text":"Antipsychotic-like profile of thioperamide, a selective H3-receptor antagonist in mice.\nExperimental and clinical evidence points to a role of central histaminergic system in the pathogenesis of schizophrenia. The present study was designed to study the effect of histamine H(3)-receptor ligands on neuroleptic-induced catalepsy, apomorphine-induced climbing behavior and amphetamine-induced locomotor activities in mice. Catalepsy was induced by haloperidol (2 mg/kg p.o.), while apomorphine (1.5 mg/kg s.c.) and amphetamine (2 mg/kg s.c.) were used for studying climbing behavior and locomotor activities, respectively. (R)-alpha-methylhistamine (RAMH) (5 microg i.c.v.) and thioperamide (THP) (15 mg/kg i.p.), per se did not cause catalepsy. Administration of THP (3.75, 7.5 and 15 mg/kg i.p.) 1 h prior to haloperidol resulted in a dose-dependent increase in the catalepsy times (P \u003c 0.05). However, pretreatment with RAMH significantly reversed such an effect of THP (15 mg/kg i.p.). RAMH per se showed significant reduction in locomotor time, distance traveled and average speed but THP (15 mg/kg i.p.) per se had no effect on these parameters. On amphetamine-induced hyperactivity, THP (3.75 and 7.5 mg/kg i.p.) reduced locomotor time, distance traveled and average speed (P \u003c 0.05). Pretreatment with RAMH (5 microg i.c.v.) could partially reverse such effects of THP (3.75 mg/kg i.p.). Climbing behavior induced by apomorphine was reduced in animals treated with THP. Such an effect was, however, reversed in presence of RAMH. THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice. Such effects of THP were reversed by RAMH indicating the involvement of histamine H(3)-receptors. Findings suggest a potential for H(3)-receptor antagonists in improving the refractory cases of schizophrenia."}

LitCoin-GeneOrGeneProduct-v0

LitCoin-GeneOrGeneProduct-v2

{"project":"LitCoin-GeneOrGeneProduct-v2","denotations":[{"id":"T1","span":{"begin":14,"end":18},"obj":"GeneOrGeneProduct"},{"id":"T2","span":{"begin":59,"end":67},"obj":"GeneOrGeneProduct"},{"id":"T3","span":{"begin":279,"end":287},"obj":"GeneOrGeneProduct"},{"id":"T4","span":{"begin":359,"end":367},"obj":"GeneOrGeneProduct"},{"id":"T5","span":{"begin":573,"end":581},"obj":"GeneOrGeneProduct"},{"id":"T6","span":{"begin":626,"end":631},"obj":"GeneOrGeneProduct"},{"id":"T7","span":{"begin":1219,"end":1226},"obj":"GeneOrGeneProduct"},{"id":"T8","span":{"begin":1404,"end":1412},"obj":"GeneOrGeneProduct"},{"id":"T9","span":{"begin":1440,"end":1447},"obj":"GeneOrGeneProduct"},{"id":"T10","span":{"begin":1567,"end":1571},"obj":"GeneOrGeneProduct"},{"id":"T11","span":{"begin":1793,"end":1817},"obj":"GeneOrGeneProduct"},{"id":"T12","span":{"begin":1857,"end":1865},"obj":"GeneOrGeneProduct"}],"text":"Antipsychotic-like profile of thioperamide, a selective H3-receptor antagonist in mice.\nExperimental and clinical evidence points to a role of central histaminergic system in the pathogenesis of schizophrenia. The present study was designed to study the effect of histamine H(3)-receptor ligands on neuroleptic-induced catalepsy, apomorphine-induced climbing behavior and amphetamine-induced locomotor activities in mice. Catalepsy was induced by haloperidol (2 mg/kg p.o.), while apomorphine (1.5 mg/kg s.c.) and amphetamine (2 mg/kg s.c.) were used for studying climbing behavior and locomotor activities, respectively. (R)-alpha-methylhistamine (RAMH) (5 microg i.c.v.) and thioperamide (THP) (15 mg/kg i.p.), per se did not cause catalepsy. Administration of THP (3.75, 7.5 and 15 mg/kg i.p.) 1 h prior to haloperidol resulted in a dose-dependent increase in the catalepsy times (P \u003c 0.05). However, pretreatment with RAMH significantly reversed such an effect of THP (15 mg/kg i.p.). RAMH per se showed significant reduction in locomotor time, distance traveled and average speed but THP (15 mg/kg i.p.) per se had no effect on these parameters. On amphetamine-induced hyperactivity, THP (3.75 and 7.5 mg/kg i.p.) reduced locomotor time, distance traveled and average speed (P \u003c 0.05). Pretreatment with RAMH (5 microg i.c.v.) could partially reverse such effects of THP (3.75 mg/kg i.p.). Climbing behavior induced by apomorphine was reduced in animals treated with THP. Such an effect was, however, reversed in presence of RAMH. THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice. Such effects of THP were reversed by RAMH indicating the involvement of histamine H(3)-receptors. Findings suggest a potential for H(3)-receptor antagonists in improving the refractory cases of schizophrenia."}

LitCoin-Disease-MeSH

{"project":"LitCoin-Disease-MeSH","denotations":[{"id":"T1","span":{"begin":195,"end":208},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":319,"end":328},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":422,"end":431},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":734,"end":743},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T5","span":{"begin":867,"end":876},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T6","span":{"begin":1174,"end":1187},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T7","span":{"begin":1616,"end":1625},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T8","span":{"begin":1656,"end":1669},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T9","span":{"begin":1915,"end":1928},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A9","pred":"originalLabel","subj":"T9","obj":"D012559"},{"id":"A1","pred":"originalLabel","subj":"T1","obj":"D012559"},{"id":"A8","pred":"originalLabel","subj":"T8","obj":"DISEASE"},{"id":"A6","pred":"originalLabel","subj":"T6","obj":"DISEASE"},{"id":"A4","pred":"originalLabel","subj":"T4","obj":"D002375"},{"id":"A7","pred":"originalLabel","subj":"T7","obj":"D002375"},{"id":"A3","pred":"originalLabel","subj":"T3","obj":"D002375"},{"id":"A5","pred":"originalLabel","subj":"T5","obj":"D002375"},{"id":"A2","pred":"originalLabel","subj":"T2","obj":"D002375"}],"text":"Antipsychotic-like profile of thioperamide, a selective H3-receptor antagonist in mice.\nExperimental and clinical evidence points to a role of central histaminergic system in the pathogenesis of schizophrenia. The present study was designed to study the effect of histamine H(3)-receptor ligands on neuroleptic-induced catalepsy, apomorphine-induced climbing behavior and amphetamine-induced locomotor activities in mice. Catalepsy was induced by haloperidol (2 mg/kg p.o.), while apomorphine (1.5 mg/kg s.c.) and amphetamine (2 mg/kg s.c.) were used for studying climbing behavior and locomotor activities, respectively. (R)-alpha-methylhistamine (RAMH) (5 microg i.c.v.) and thioperamide (THP) (15 mg/kg i.p.), per se did not cause catalepsy. Administration of THP (3.75, 7.5 and 15 mg/kg i.p.) 1 h prior to haloperidol resulted in a dose-dependent increase in the catalepsy times (P \u003c 0.05). However, pretreatment with RAMH significantly reversed such an effect of THP (15 mg/kg i.p.). RAMH per se showed significant reduction in locomotor time, distance traveled and average speed but THP (15 mg/kg i.p.) per se had no effect on these parameters. On amphetamine-induced hyperactivity, THP (3.75 and 7.5 mg/kg i.p.) reduced locomotor time, distance traveled and average speed (P \u003c 0.05). Pretreatment with RAMH (5 microg i.c.v.) could partially reverse such effects of THP (3.75 mg/kg i.p.). Climbing behavior induced by apomorphine was reduced in animals treated with THP. Such an effect was, however, reversed in presence of RAMH. THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice. Such effects of THP were reversed by RAMH indicating the involvement of histamine H(3)-receptors. Findings suggest a potential for H(3)-receptor antagonists in improving the refractory cases of schizophrenia."}

LitCoin_Mondo_095

{"project":"LitCoin_Mondo_095","denotations":[{"id":"T1","span":{"begin":195,"end":208},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":1915,"end":1928},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"0005090"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"0005090"}],"text":"Antipsychotic-like profile of thioperamide, a selective H3-receptor antagonist in mice.\nExperimental and clinical evidence points to a role of central histaminergic system in the pathogenesis of schizophrenia. The present study was designed to study the effect of histamine H(3)-receptor ligands on neuroleptic-induced catalepsy, apomorphine-induced climbing behavior and amphetamine-induced locomotor activities in mice. Catalepsy was induced by haloperidol (2 mg/kg p.o.), while apomorphine (1.5 mg/kg s.c.) and amphetamine (2 mg/kg s.c.) were used for studying climbing behavior and locomotor activities, respectively. (R)-alpha-methylhistamine (RAMH) (5 microg i.c.v.) and thioperamide (THP) (15 mg/kg i.p.), per se did not cause catalepsy. Administration of THP (3.75, 7.5 and 15 mg/kg i.p.) 1 h prior to haloperidol resulted in a dose-dependent increase in the catalepsy times (P \u003c 0.05). However, pretreatment with RAMH significantly reversed such an effect of THP (15 mg/kg i.p.). RAMH per se showed significant reduction in locomotor time, distance traveled and average speed but THP (15 mg/kg i.p.) per se had no effect on these parameters. On amphetamine-induced hyperactivity, THP (3.75 and 7.5 mg/kg i.p.) reduced locomotor time, distance traveled and average speed (P \u003c 0.05). Pretreatment with RAMH (5 microg i.c.v.) could partially reverse such effects of THP (3.75 mg/kg i.p.). Climbing behavior induced by apomorphine was reduced in animals treated with THP. Such an effect was, however, reversed in presence of RAMH. THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice. Such effects of THP were reversed by RAMH indicating the involvement of histamine H(3)-receptors. Findings suggest a potential for H(3)-receptor antagonists in improving the refractory cases of schizophrenia."}

LitCoin-GeneOrGeneProduct-v3

{"project":"LitCoin-GeneOrGeneProduct-v3","denotations":[{"id":"T1","span":{"begin":264,"end":287},"obj":"GeneOrGeneProduct"},{"id":"T2","span":{"begin":626,"end":631},"obj":"GeneOrGeneProduct"},{"id":"T3","span":{"begin":1793,"end":1817},"obj":"GeneOrGeneProduct"}],"text":"Antipsychotic-like profile of thioperamide, a selective H3-receptor antagonist in mice.\nExperimental and clinical evidence points to a role of central histaminergic system in the pathogenesis of schizophrenia. The present study was designed to study the effect of histamine H(3)-receptor ligands on neuroleptic-induced catalepsy, apomorphine-induced climbing behavior and amphetamine-induced locomotor activities in mice. Catalepsy was induced by haloperidol (2 mg/kg p.o.), while apomorphine (1.5 mg/kg s.c.) and amphetamine (2 mg/kg s.c.) were used for studying climbing behavior and locomotor activities, respectively. (R)-alpha-methylhistamine (RAMH) (5 microg i.c.v.) and thioperamide (THP) (15 mg/kg i.p.), per se did not cause catalepsy. Administration of THP (3.75, 7.5 and 15 mg/kg i.p.) 1 h prior to haloperidol resulted in a dose-dependent increase in the catalepsy times (P \u003c 0.05). However, pretreatment with RAMH significantly reversed such an effect of THP (15 mg/kg i.p.). RAMH per se showed significant reduction in locomotor time, distance traveled and average speed but THP (15 mg/kg i.p.) per se had no effect on these parameters. On amphetamine-induced hyperactivity, THP (3.75 and 7.5 mg/kg i.p.) reduced locomotor time, distance traveled and average speed (P \u003c 0.05). Pretreatment with RAMH (5 microg i.c.v.) could partially reverse such effects of THP (3.75 mg/kg i.p.). Climbing behavior induced by apomorphine was reduced in animals treated with THP. Such an effect was, however, reversed in presence of RAMH. THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice. Such effects of THP were reversed by RAMH indicating the involvement of histamine H(3)-receptors. Findings suggest a potential for H(3)-receptor antagonists in improving the refractory cases of schizophrenia."}

LitCoin-MeSH-Disease-2

{"project":"LitCoin-MeSH-Disease-2","denotations":[{"id":"T1","span":{"begin":195,"end":208},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":319,"end":328},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":422,"end":431},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":734,"end":743},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T5","span":{"begin":867,"end":876},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T6","span":{"begin":1174,"end":1187},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T7","span":{"begin":1616,"end":1625},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T8","span":{"begin":1656,"end":1669},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T9","span":{"begin":1915,"end":1928},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A8","pred":"ID:","subj":"T8","obj":"DISEASE"},{"id":"A2","pred":"ID:","subj":"T2","obj":"D002375"},{"id":"A6","pred":"ID:","subj":"T6","obj":"DISEASE"},{"id":"A9","pred":"ID:","subj":"T9","obj":"D012559"},{"id":"A5","pred":"ID:","subj":"T5","obj":"D002375"},{"id":"A7","pred":"ID:","subj":"T7","obj":"D002375"},{"id":"A4","pred":"ID:","subj":"T4","obj":"D002375"},{"id":"A3","pred":"ID:","subj":"T3","obj":"D002375"},{"id":"A1","pred":"ID:","subj":"T1","obj":"D012559"}],"text":"Antipsychotic-like profile of thioperamide, a selective H3-receptor antagonist in mice.\nExperimental and clinical evidence points to a role of central histaminergic system in the pathogenesis of schizophrenia. The present study was designed to study the effect of histamine H(3)-receptor ligands on neuroleptic-induced catalepsy, apomorphine-induced climbing behavior and amphetamine-induced locomotor activities in mice. Catalepsy was induced by haloperidol (2 mg/kg p.o.), while apomorphine (1.5 mg/kg s.c.) and amphetamine (2 mg/kg s.c.) were used for studying climbing behavior and locomotor activities, respectively. (R)-alpha-methylhistamine (RAMH) (5 microg i.c.v.) and thioperamide (THP) (15 mg/kg i.p.), per se did not cause catalepsy. Administration of THP (3.75, 7.5 and 15 mg/kg i.p.) 1 h prior to haloperidol resulted in a dose-dependent increase in the catalepsy times (P \u003c 0.05). However, pretreatment with RAMH significantly reversed such an effect of THP (15 mg/kg i.p.). RAMH per se showed significant reduction in locomotor time, distance traveled and average speed but THP (15 mg/kg i.p.) per se had no effect on these parameters. On amphetamine-induced hyperactivity, THP (3.75 and 7.5 mg/kg i.p.) reduced locomotor time, distance traveled and average speed (P \u003c 0.05). Pretreatment with RAMH (5 microg i.c.v.) could partially reverse such effects of THP (3.75 mg/kg i.p.). Climbing behavior induced by apomorphine was reduced in animals treated with THP. Such an effect was, however, reversed in presence of RAMH. THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice. Such effects of THP were reversed by RAMH indicating the involvement of histamine H(3)-receptors. Findings suggest a potential for H(3)-receptor antagonists in improving the refractory cases of schizophrenia."}

LitCoin-MONDO_bioort2019

{"project":"LitCoin-MONDO_bioort2019","denotations":[{"id":"T1","span":{"begin":195,"end":208},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":319,"end":328},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":422,"end":431},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":734,"end":743},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T5","span":{"begin":867,"end":876},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T6","span":{"begin":1174,"end":1187},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T7","span":{"begin":1616,"end":1625},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T8","span":{"begin":1656,"end":1669},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T9","span":{"begin":1915,"end":1928},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A5","pred":"#label","subj":"T5","obj":"D002375"},{"id":"A6","pred":"#label","subj":"T6","obj":"DISEASE"},{"id":"A1","pred":"#label","subj":"T1","obj":"D012559"},{"id":"A7","pred":"#label","subj":"T7","obj":"D002375"},{"id":"A4","pred":"#label","subj":"T4","obj":"D002375"},{"id":"A2","pred":"#label","subj":"T2","obj":"D002375"},{"id":"A9","pred":"#label","subj":"T9","obj":"D012559"},{"id":"A8","pred":"#label","subj":"T8","obj":"DISEASE"},{"id":"A3","pred":"#label","subj":"T3","obj":"D002375"}],"text":"Antipsychotic-like profile of thioperamide, a selective H3-receptor antagonist in mice.\nExperimental and clinical evidence points to a role of central histaminergic system in the pathogenesis of schizophrenia. The present study was designed to study the effect of histamine H(3)-receptor ligands on neuroleptic-induced catalepsy, apomorphine-induced climbing behavior and amphetamine-induced locomotor activities in mice. Catalepsy was induced by haloperidol (2 mg/kg p.o.), while apomorphine (1.5 mg/kg s.c.) and amphetamine (2 mg/kg s.c.) were used for studying climbing behavior and locomotor activities, respectively. (R)-alpha-methylhistamine (RAMH) (5 microg i.c.v.) and thioperamide (THP) (15 mg/kg i.p.), per se did not cause catalepsy. Administration of THP (3.75, 7.5 and 15 mg/kg i.p.) 1 h prior to haloperidol resulted in a dose-dependent increase in the catalepsy times (P \u003c 0.05). However, pretreatment with RAMH significantly reversed such an effect of THP (15 mg/kg i.p.). RAMH per se showed significant reduction in locomotor time, distance traveled and average speed but THP (15 mg/kg i.p.) per se had no effect on these parameters. On amphetamine-induced hyperactivity, THP (3.75 and 7.5 mg/kg i.p.) reduced locomotor time, distance traveled and average speed (P \u003c 0.05). Pretreatment with RAMH (5 microg i.c.v.) could partially reverse such effects of THP (3.75 mg/kg i.p.). Climbing behavior induced by apomorphine was reduced in animals treated with THP. Such an effect was, however, reversed in presence of RAMH. THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice. Such effects of THP were reversed by RAMH indicating the involvement of histamine H(3)-receptors. Findings suggest a potential for H(3)-receptor antagonists in improving the refractory cases of schizophrenia."}

LitCoin-NCBITaxon-2

{"project":"LitCoin-NCBITaxon-2","denotations":[{"id":"T1","span":{"begin":82,"end":86},"obj":"OrganismTaxon"},{"id":"T2","span":{"begin":416,"end":420},"obj":"OrganismTaxon"},{"id":"T3","span":{"begin":1715,"end":1719},"obj":"OrganismTaxon"}],"text":"Antipsychotic-like profile of thioperamide, a selective H3-receptor antagonist in mice.\nExperimental and clinical evidence points to a role of central histaminergic system in the pathogenesis of schizophrenia. The present study was designed to study the effect of histamine H(3)-receptor ligands on neuroleptic-induced catalepsy, apomorphine-induced climbing behavior and amphetamine-induced locomotor activities in mice. Catalepsy was induced by haloperidol (2 mg/kg p.o.), while apomorphine (1.5 mg/kg s.c.) and amphetamine (2 mg/kg s.c.) were used for studying climbing behavior and locomotor activities, respectively. (R)-alpha-methylhistamine (RAMH) (5 microg i.c.v.) and thioperamide (THP) (15 mg/kg i.p.), per se did not cause catalepsy. Administration of THP (3.75, 7.5 and 15 mg/kg i.p.) 1 h prior to haloperidol resulted in a dose-dependent increase in the catalepsy times (P \u003c 0.05). However, pretreatment with RAMH significantly reversed such an effect of THP (15 mg/kg i.p.). RAMH per se showed significant reduction in locomotor time, distance traveled and average speed but THP (15 mg/kg i.p.) per se had no effect on these parameters. On amphetamine-induced hyperactivity, THP (3.75 and 7.5 mg/kg i.p.) reduced locomotor time, distance traveled and average speed (P \u003c 0.05). Pretreatment with RAMH (5 microg i.c.v.) could partially reverse such effects of THP (3.75 mg/kg i.p.). Climbing behavior induced by apomorphine was reduced in animals treated with THP. Such an effect was, however, reversed in presence of RAMH. THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice. Such effects of THP were reversed by RAMH indicating the involvement of histamine H(3)-receptors. Findings suggest a potential for H(3)-receptor antagonists in improving the refractory cases of schizophrenia."}

LitCoin-Chemical-MeSH-CHEBI

LitCoin-training-merged

PubmedHPO

{"project":"PubmedHPO","denotations":[{"id":"T1","span":{"begin":195,"end":208},"obj":"HP_0100753"},{"id":"T2","span":{"begin":1174,"end":1187},"obj":"HP_0000752"},{"id":"T3","span":{"begin":1656,"end":1669},"obj":"HP_0000752"},{"id":"T4","span":{"begin":1915,"end":1928},"obj":"HP_0100753"}],"text":"Antipsychotic-like profile of thioperamide, a selective H3-receptor antagonist in mice.\nExperimental and clinical evidence points to a role of central histaminergic system in the pathogenesis of schizophrenia. The present study was designed to study the effect of histamine H(3)-receptor ligands on neuroleptic-induced catalepsy, apomorphine-induced climbing behavior and amphetamine-induced locomotor activities in mice. Catalepsy was induced by haloperidol (2 mg/kg p.o.), while apomorphine (1.5 mg/kg s.c.) and amphetamine (2 mg/kg s.c.) were used for studying climbing behavior and locomotor activities, respectively. (R)-alpha-methylhistamine (RAMH) (5 microg i.c.v.) and thioperamide (THP) (15 mg/kg i.p.), per se did not cause catalepsy. Administration of THP (3.75, 7.5 and 15 mg/kg i.p.) 1 h prior to haloperidol resulted in a dose-dependent increase in the catalepsy times (P \u003c 0.05). However, pretreatment with RAMH significantly reversed such an effect of THP (15 mg/kg i.p.). RAMH per se showed significant reduction in locomotor time, distance traveled and average speed but THP (15 mg/kg i.p.) per se had no effect on these parameters. On amphetamine-induced hyperactivity, THP (3.75 and 7.5 mg/kg i.p.) reduced locomotor time, distance traveled and average speed (P \u003c 0.05). Pretreatment with RAMH (5 microg i.c.v.) could partially reverse such effects of THP (3.75 mg/kg i.p.). Climbing behavior induced by apomorphine was reduced in animals treated with THP. Such an effect was, however, reversed in presence of RAMH. THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice. Such effects of THP were reversed by RAMH indicating the involvement of histamine H(3)-receptors. Findings suggest a potential for H(3)-receptor antagonists in improving the refractory cases of schizophrenia."}